Prelude Therapeutics (PRLD)

• Market cap: $71.5M
• 1 day: 46.40%
• 5 days: 63.19%
• 1 month: 35.18%
• 3 months: -49.02%
• 6 months: -64.96%
• Year to date: -68.06%
• 1 year: -67.25%
• 5 years: -95.04%
• 10 years: -95.04%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Employees: 128

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

15% more funds holding

Funds holding: 61 [Q2] → 70 (+9) [Q3]

3.5% more ownership

Funds ownership: 81.29% [Q2] → 84.79% (+3.5%) [Q3]

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

10% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 21

43% less capital invested

Capital invested by funds: $130M [Q2] → $74M (-$56.3M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 208% upside
• Avg. target: $4.50 246% upside
• High target: $5 285% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Reni Benjamin 17% 1-year accuracy 6 / 36 met price target	208% upside $4	Market Outperform Reiterated	11 Dec 2024
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target	285% upside $5	Buy Reiterated	8 Nov 2024